Last reviewed · How we verify

NCT05593679

A Multi-center Cardiac PYP Scan Registry in Taiwan

Recruiting now Last updated 29 July 2024
What this trial tests

trial testing Tc-99m PYP Cardiac scan in Heart Failure in 1,000 participants. Currently enrolling.

Timeline
1 November 2022
Primary endpoint
29 August 2027
31 December 2027

Quick facts

Lead sponsorFar Eastern Memorial Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment1,000
Start date1 November 2022
Primary completion29 August 2027
Estimated completion31 December 2027
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Far Eastern Memorial Hospital

Who can join

20 and older, any sex, with Heart Failure or Cardiac Amyloidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Amyloid deposition in the heart is called cardiac amyloidosis (CA); 95% is immunoglobulin light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR). Hereditary (ATTRm) or wild-type (ATTRwt) depends on whether the ATTRm gene is mutated or not. The most common mutation in Taiwan is A97S, 80% have left ventricular hypertrophy. The good prognosis depends on early diagnosis and correct treatment strategy. Bone-avid tracers such as 99mTc-PYP/DPD/HMDP could detect CA. The mechanism is not clear yet, which may be related to the microcalcification. AL amyloidosis is mostly between visual score grade 0-2, and ATTR-CM is usually grade≥2 on PYP scan, or heart to contralateral (H/CL) ratio, and it might replace invasive myocardial biopsy. However, there are no large-scale clinical studies, lack of standardization data, and limited information in comparison between clinical and imaging parameters. The project will enroll patients with suspected or diagnosed with CA according to CA diagnostic algorithm. Clinical data and image parameters are collected and compared. The project aims to set up prediction models based on the multi-parameters of PYP scan using artificial intelligence technology, including imaging registration and alignment technology, and standardization. The investigators further use the key cardiovascular data elements and imaging-derived database using model training network to extract image features to develop the diagnostic and prognostic prediction models, which are expected to validate the clinical significance and improve patient-centric performance and efficient clinical decision making.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

Other Far Eastern Memorial Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05593679.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing